Table 1 Summary of included studies.

Trial	Patient number	Trial design	Country or region	Median age (years)	Node negative	Hormone receptor positive	Adjuvant chemotherapy^a	Non-inferiority margin of HR	HR with 95% CI	Shortened time (month)	Endpoint	Median follow-up (year)
PHARE⁶	1691	Non-inferiority	France	55	55%	61%	A + T 73%; A 15%; T 11%	1.15	1.08 (0.93–1.25)	6	DFS	7.5
HORG⁷	481	Non-inferiority	Greece	55	21%	67%	Unspecified	1.53	1.57 (0.86–2.10)	6	DFS	3
Short-HER⁹	1254	Non-inferiority	Italy	55	54%	68%	A + T 100%	1.29	1.13 (0.85–1.49)^b	9.9	DFS	6
SOLD⁸	2174	Non-inferiority	Finland	56	60%	66%	A + T 100%	1.3	1.39 (1.08–1.80)^b	9.9	DFS	5.2
PERSEPHONE¹⁰	4088	Non-inferiority	UK	56	58%	69%	A + T 48%; A 42%; T 10%	1.29	1.07 (0.90–1.27)^b	6	DFS	5.4
E2198²⁴	227	Superiority	USA	49	0	62%	Unspecified	NA	1.18 (0.56–2.44)	12	DFS	6.4
NCCTG N9831¹²	1944	Superiority	USA	51	15%	54%	A + T 100%	NA	1.67 (1.47–1.89)	12	DFS	8.4
NSABP B-31¹²	2102	Superiority	USA	49	0	56%	A + T 100%	NA	1.67 (1.47–1.89)	12	DFS	8.4
HERA²⁵	3401	Superiority	Global	49	32%	45%	A + T 26%; A 68%	NA	1.45 (1.27–1.69)^c	12	DFS	8
BCIRG-006¹¹	2147	Superiority	USA	48	29%	54%	A + T 100%	NA	1.39 (1.18–1.64)	12	DFS	10.3
PACS04²⁶	528	Superiority	Europe	49	0	60%	A + T 47%; A 53%	NA	1.16 (0.82–1.64)	12	DFS	3.9
NOAH²⁷	235	Superiority	Global	52	15%	36%	A + T 100%	NA	1.69 (1.11–2.63)	12	EFS	5.4

CI confidence interval, DFS disease-free survival, EFS event-free survival, HR hazard ratio, NA not applicable.
^aA, Anthracycline-based; T, Taxane-based; A + T, anthracycline and taxane-containing.
^bCalculation of the 95% CI using the 90% CI provided in the original paper.
^cUsing the censored analysis in HERA trial. The censored analysis removed the crossover patients’ follow-up, which is a confounding factor, after the start of treatment with trastuzumab.

Quick links

Search